JOINN LABORATORIES(6127.HK):WAITING LONGER FOR RECOVERY TO MATERIALIZE
Nomura Adjusts Joinn Laboratories' Price Target to HK$10.41 From HK$12.60, Keeps at Neutral
Guoxin Securities released a research report on April 15 stating that it gave Zhaoyan New Pharmaceutical (603127.SH) a purchase rating. The main reasons for the rating include: 1) revenue is basically flat throughout the year, and the profit side is under
Zhaoyan New Pharmaceutical (603127): Revenue was basically flat for the full year of 2023, and the results of the internationalization strategy showed results
Bank Rating | Lyon: Upgraded Tiger Pharmaceuticals and Zhaoyan New Drug Ratings Benefit from Innovative Drug Support Policies
Zhaoyan Pharmaceutical (603127) 2023 Annual Report Review: Profitability Under Short-term Pressure, Internationalization Continues to Advance
Zhaoyan New Pharmaceutical (603127): Profitability under short-term pressure, internationalization continues to advance
Zhaoyan Pharmaceutical (603127): Changes in biological asset value affect profits and await gradual recovery in 2024
Zhaoyan Pharmaceutical (6127.HK): It will take time for terminal demand to recover, and 2024 will still face challenges
Zhaoyan Pharmaceutical (603127): High overseas growth, local economy waiting for recovery
Zhaoyan Pharmaceutical (603127) 2023 Annual Report Review: Multiple Factors Influence Profits and Rapid Overseas Business Development
Zhaoyan Pharmaceutical (603127): Domestic business is under short-term pressure, and overseas revenue is growing steadily
Zhaoyan New Pharmaceutical (603127): Revenue is in line with expectations, changes in fair value have a big impact and await the gradual recovery of the industry
Zhaoyan Pharmaceutical (603127): Stable growth in main business revenue and fluctuations in fair value of biological assets
Zhaoyan Pharmaceutical (6127.HK): Lowering profit forecast and target price
Nomura Downgrades Joinn Laboratories (China) to Neutral From Buy, Adjusts Price Target to HK$12.60 From HK$20.93
Nomura: Downgrade the rating of Shoyan Pharmaceutical (06127) to “neutral” and reduce the target price by 40% to HK$12.6
Zhaoyan New Pharmaceutical (603127) 2023 Third Quarter Report Review: Apparent Influence by Fluctuations in Biological Assets, Main Business Continues Good Growth Trend
Zhaoyan New Pharmaceuticals (603127): Slowing growth capacity and improving profitability
Research Report Nuggets | Zhongtai Securities: Zhaoyan New Pharmaceutical's Q3 Revenue Continues to Be Stable, Maintains “Buy” Rating
No Data